Investigational New Drugs
-
Publication Venue For
- Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R -mutant pancreatic ductal adenocarcinoma.. 39:821-828. 2021
- An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer. 32:1258-1268. 2014
- Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8). 29:1517-1518. 2011
- Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors.. 26:445-454. 2008
- Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium.. 26:151-158. 2008
- A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study.. 24:515-520. 2006
- Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study.. 24:537-542. 2006
- Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study.. 24:335-341. 2006
- A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study.. 23:485-487. 2005
- Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers.. 23:489-493. 2005
- Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy.. 23:235-239. 2005
- Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98).. 23:51-56. 2005
- A phase I surrogate endpoint study of SU6668 in patients with solid tumors.. 22:459-466. 2004
- A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study.. 22:467-473. 2004
- A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study.. 22:335-341. 2004
- Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer.. 22:307-313. 2004
- Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study.. 22:91-97. 2004
- Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041).. 22:83-89. 2004
- Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer.. 20:419-424. 2002
- Current approaches and future strategies for pancreatic carcinoma.. 18:43-56. 2000
- Compatibility and stability of bryostatin 1 in infusion devices.. 16:227-236. 1998
- Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma.. 16:341-346. 1998
- Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer.. 13:355-358. 1996
- Mitomycin C and menadione for the treatment of lung cancer: a phase II trial.. 13:157-162. 1995
- P-glycoprotein mediated resistance to 5'-nor-anhydro-vinblastine (Navelbine).. 13:13-21. 1995
- Phase II trial of intravenous melphalan in advanced colorectal carcinoma.. 12:133-136. 1994
- Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma.. 11:67-69. 1993
- Phase II study of gemcitabine in advanced colorectal adenocarcinoma.. 10:323-325. 1992
- Phase II study of didemnin B in advanced colorectal cancer.. 10:211-213. 1992
- An efficient multiple-exposure analysis of the toxicity of crisnatol, a DNA intercalator in phase II clinical trials.. 10:1-15. 1992
- Phase II trial of fazarabine in advanced colorectal carcinoma.. 10:39-42. 1992
- Amelioration of thrombocytopenia with concomitant ornithine in sarcoma-bearing rats receiving high dose difluoromethylornithine.. 9:321-326. 1991
- Phase II study of amonafide in advanced pancreatic adenocarcinoma.. 9:353-356. 1991
- Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas.. 9:369-371. 1991
- Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma.. 9:257-259. 1991
- Phase II study of 4'-deoxydoxorubicin (esorubicin) in advanced or metastatic adenocarcinoma of the stomach.. 9:83-85. 1991
- 3-Deazaguanine: report of a phase I trial and drug-related cardiac toxicity.. 8:369-376. 1990
- Phase I evaluation of diaziquone in childhood cancer. A Pediatric Oncology Group study.. 8:167-170. 1990
- Phase I trial of 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU) terminated by severe neurologic toxicity.. 7:195-201. 1989
- Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma.. 6:47-50. 1988
- Mitoxantrone: propensity for free radical formation and lipid peroxidation--implications for cardiotoxicity.. 3:95-99. 1985
- Phase I-II trial of mitoxantrone in acute leukemia: an interim report.. 3:213-217. 1985